Related Experiment Video
Updated: Aug 4, 2026
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92
1Department of Hematology, B.C. Cancer Agency, B.C. Cancer Research Centre, Vancouver, Canada.
Abstract:
In this work, we evaluated the potential of the natural killer (NK) cell line NK-92 and its IL-2-independent variants NK-92MI and CI, as immunotherapy for melanoma. In vitro, we found that NK-92 was much more cytotoxic to a number of human melanoma cell lines than lymphokine-activated killer (LAK) cells, particularly at low effector/target (E:T) ratios. In vivo treatment of mice challenged with MEWO melanoma cells with i.v. administered NK-92 and NK-92-MI resulted in a 1.5-2.5-fold increase in average length of survival. NK-92, MI, and CI were also effective against the WM1341 cell line, causing a 2-5-fold increase in survival when administered before the malignant cells. With s.c. injection, MEWO and WM1341 caused a primary tumor mass, secondary tumors, and metastatic cells. NK-92 cells reduced WM1341 primary tumor size by 40-90% and MEWO tumors by 30-75%. Similar results were seen with NK-92MI and CI. These data show that NK-92 cells are highly cytotoxic to human melanoma cells in vitro and in vivo and suggest that treatment with NK-92 cells may be a potentially effective immunotherapeutic modality in melanoma.
Insights
Natural killer (NK) cell line NK-92 and its variants show potent anti-melanoma activity. These cells effectively reduce tumor size and increase survival in melanoma models, suggesting promise for immunotherapy.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Melanoma remains a significant health concern with limited effective treatments.
- Immunotherapy offers a promising avenue for cancer treatment.
- Natural Killer (NK) cells are crucial components of the innate immune system with cytotoxic capabilities.
Purpose of the Study:
- To evaluate the potential of the NK-92 cell line and its IL-2-independent variants (NK-92MI and CI) as an immunotherapy for melanoma.
- To assess the in vitro and in vivo efficacy of NK-92 cells against human melanoma cell lines.
Main Methods:
- In vitro cytotoxicity assays comparing NK-92 cells with lymphokine-activated killer (LAK) cells against melanoma cell lines.
- In vivo studies involving intravenous and subcutaneous administration of NK-92 cells in mouse models challenged with melanoma cells.
- Evaluation of survival rates and primary tumor size reduction in treated mice.
Main Results:
- NK-92 cells demonstrated significantly higher cytotoxicity against human melanoma cell lines in vitro compared to LAK cells, especially at low effector/target ratios.
- Intravenous administration of NK-92 and NK-92MI cells resulted in a 1.5-2.5-fold increase in average survival time in mice with MEWO melanoma.
- Subcutaneous administration of NK-92 cells led to a 40-90% reduction in primary tumor size for WM1341 and 30-75% for MEWO melanoma models.
Conclusions:
- NK-92 cell lines exhibit potent cytotoxic activity against human melanoma cells both in vitro and in vivo.
- NK-92, NK-92MI, and NK-92CI cells show significant therapeutic potential in preclinical melanoma models.
- These findings suggest that NK-92 cell-based immunotherapy could be a viable treatment strategy for melanoma.
